Objective: The mechanism by which the cardiac Na/K ATPase (NKA) is regulated by phosphorylation is controversial. We have used the perforated-patch technique to limit cell dialysis and maintain conditions as near physiological as possible. Methods: NKA pump current (I p ) was measured in isolated guinea pig ventricular myocytes, and its components (I a1 and I a2 ) defined by their differing dihydroouabain sensitivities. Results: Treatment with 1 Amol/l forskolin for 4 min at 35 8C caused a significant increase in I a1 of 36F15% ( Pb0.05, n=6), but no change in I a2 . The presence of the PKA selective inhibitor H89 (50 Amol/l) throughout the protocol blocked the effect of the forskolin on I a1 . Treatment with H89 alone did not change I a1 or I a2 . Isoelectric focusing gels of the NKA a1 subunit demonstrated six charge states, which were unaltered following treatment with forskolin. Western blots using an antibody specific for the PKA phosphorylation consensus site on the a1 subunit showed no change in the phosphorylation status of this residue following forskolin treatment. The sarcolemmal protein phospholemman (PLM) was found associated with NKA a1 but not a2 subunits by immunoprecipitation and immunofluorescence. PLM was phosphorylated at serine 68, but not 63, following treatment with forskolin. Conclusions: PKA-dependent, a1-specific NKA activation may be mediated through phosphorylation of the accessory protein PLM, rather than direct a1 subunit phosphorylation.
Introduction
In excitable cells, the transmembrane sodium (Na) gradient, established by the Na/K ATPase (NKA), is essential for a plethora of cellular functions. In cardiac cells, approximately 40% of the resting ATP consumption has been attributed to the turnover of the NKA [1] . The metabolic energy invested in establishing the Na gradient is then used to drive numerous ionic and metabolic transport processes and is a key prerequisite for the control of cell excitability and volume. Alterations in the activity and regulation of the NKA can therefore have a profound effect on normal cellular function.
In many tissues, the cAMP-PKA signaling cascade is involved in NKA regulation (for review, see Ref. [2] ); however, the effect of PKA activation on NKA activity is tissue-and model-specific. In the kidney, PKA activation increases NKA activity in rat proximal convoluted tubule cells through insertion of additional pump units in the plasma membrane [3] . However, other researchers report that forskolin has an inhibitory effect on NKA activity in COS-7 cells, with no effect on the amount of pump protein at the membrane [4] .
There is no evidence that the PKA cascade alters NKA expression at the cell surface in ventricular myocytes. In guinea-pig ventricular myocytes, isoprenaline has a Ca 2+ -modulated effect on NKA [5] . PKA-dependent, isoprenaline-induced inhibition of NKA at low intracellular Ca 2+ has been described in guinea-pig myocytes [6, 7] . However, other researchers have reported that, in the same cell type, forskolin activates NKA at relatively low intracellular Ca 2+ [8] . It has also been reported that PKA stimulation in guinea-pig ventricular myocytes alters the activity of the predominant (low ouabain-affinity) a1 isoform of NKA but not the a2 isoform [9] . All these studies used the whole-cell voltage-clamp technique, which dialyses the cytoplasm and may alter relevant intracellular messenger cascades, while clamping the intracellular ion concentrations to those in the pipette. In the present study, the perforated patch technique has been employed to minimize these limitations.
While PKA activation has been demonstrated to cause phosphorylation of the a1 subunit of NKA in studies on purified protein [10, 11] , there is limited evidence for phosphorylation of NKA by PKA in living cells or tissues [12, 13] . Indeed, crystallographic data suggest that the postulated PKA phosphorylation site in the a1 subunit is inaccessible to the enzyme [14] . If PKA stimulation does not act via direct phosphorylation of the NKA a subunit, then alternative accessory protein targets must be considered. We have recently reported a substantial, ischemiainduced, PKA-dependent activation of NKA activity in sarcolemmal membranes purified from rat hearts [15] . This coincided with phosphorylation of phospholemman (PLM, FXYD1) in this tissue. PLM is the major sarcolemmal substrate for PKA and PKC in the heart [16] [17] [18] and belongs to the FXYD family of low molecular mass proteins that act as tissue-specific regulators of NKA [19] .
The aim of the present study was therefore to investigate phosphoregulation of NKA in cardiac myocytes under aerobic conditions. We have investigated the immediate effects of PKA activation on NKA. Using whole-cell voltage clamping and the perforated-patch technique, we show that acute activation of PKA with forskolin induces an isoform-specific increase in a1 but not a2 pump current, and this activation is associated with the phosphorylation of PLM at serine 68. The implications of this for cardiac function will be discussed.
Materials and methods

Animals
All animals used in this study received humane care in accordance with bGuidance on the Operation of the Animals (Scientific Procedures) Act of 1986Q published by HM Stationery Office, London UK and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . This study was also subjected to local ethical review by the Ethical Review Process Committee of King's College London.
Cell isolation
Guinea-pig and rat ventricular myocytes were isolated, as described previously [20, 21] . The yield of rod-shaped cells was typically~70%. The cell suspension was allowed to stand at room temperature for 1 h before use.
cAMP assay procedure
Cells (treated with forskolin, 1 Amol/l or vehicle, 4 min at 35 8C) were resuspended in phosphate buffer from a commercially available cAMP enzyme immunoassay kit (Cayman Chemical, MI, USA) supplemented with 10% trichloroacetic acid, at a volume of 100 Al buffer per mg protein. The cAMP assay was used according to the manufacturer's directions. cAMP content of cells was normalized to cell protein content, which was determined using the BioRad protein assay reagent.
Voltage clamping
Single isolated guinea-pig ventricular myocytes were voltage-clamped using the perforated-patch technique. Patch electrodes were made from borosilicate glass capillaries (Clark Electromedical Instruments, Reading, UK) and were fire-polished (DMG Universal Puller, Zeitz-Instrumente Ventreibs GmbH, Germany). The electrodes had a resistance of 1-2 MV when filled with the standard pipette solution. Current signals were recorded using an Axopatch 1-C single electrode voltage-clamp amplifier (Axon Instruments, USA) controlled by a microcomputer running pClamp software (v.6, Axon Instruments). A gigaohm seal was rapidly established between the electrode and the cell surface, and series resistance was monitored by a repetitive +5 mV pulse (5msec duration) from a holding potential of À40 mV. The membrane patch was allowed to permeabilize, and series resistance typically fell to b20 MV within 10 min.
Current signals were filtered at 1 kHz and sampled at 3 kHz and converted into conductance units by normalizing current records to cell capacitance. The typical cell size used in these experiments, as defined by cell capacitance, was 106F7 pF (n=22).
The pipette and extracellular solutions were designed to inhibit all voltage-gated channels and the Na/Ca exchanger. Under these conditions, the Na/K pump current (I p ) can be defined as that inhibitable by the removal of extracellular K or the addition of 1 mmol/l dihydroouabain (DHO). Inasmuch as the DHO-sensitive and K-sensitive pump currents are identical (data not shown), we have defined the whole-cell Na/K pump current as that sensitive to the removal of extracellular K.
The IC 50 for DHO block of a2-mediated pump current (I a2 ) is 0.75 Amol/l and, for a1-mediated current (I a1 ), the IC 50 is 75 Amol/l. The contributions of the a1 and a2 isoforms of NKA to total pump current were therefore defined by their respective sensitivities to DHO. To block I a2 5 Amol/l DHO was used, while 1 mmol/l DHO or K-free extracellular solution blocks both components of I p . The use of DHO to distinguish the contributions of NKA isoforms to I p in guinea-pig ventricular myocytes is well established and has been characterized in detail elsewhere [9] .
Solutions
All studies were performed at 35 8C. Solutions were made up using deionised water with Analar Grade chemicals (BDH, UK). The standard pipette solution contained (in mmol/l) NaCl 140, KCl 5, MgCl 2 1, aspartic acid 25, HEPES 10, pH 7.16. Amphotericin B (from Streptomyces, Sigma, UK; 30 mg/ml) in DMSO was added to the pipette solution on the day of use to a final concentration of 225 Ag/ml (DMSO=0.74% v/v). The standard extracellular solution contained (in mmol/l) NaCl 140, KCl 5, MgCl 2 1, NiCl 2 2, BaCl 2 1, glucose 10, HEPES 5, pH 7.36. In some experiments where forskolin was used to raise cAMP, a chloride-balanced extracellular test solution was used to limit cAMP-activated Cl currents. In this chloride-balanced solution, NaCl was lowed to 9.5 mmol/l and replaced with 130.5 mmol/l Na isethionate. KCl was replaced with 5 mmol/l K isethionate, and glibenclamide (200 Amol/l) and 4,4V-Diisothiocyanatostilbene-2,2V-disulfonic acid (DIDS; 1 mmol/l) were also added to further limit Cl currents. K-free extracellular solutions were made by removing KCl in the solution with no correction for osmolarity.
Quantitative immunoblotting
Myocytes were treated with forskolin or PMA, and aliquots of cell suspension mixed with SDS-PAGE or isoelectric focusing loading buffer immediately in order to ensure phosphatases were unable to dephosphorylate proteins prior to analysis. SDS-PAGE, isoelectric focusing, and quantitative immunoblotting were carried out as described previously [15] .
Antibodies
All NKA subunits and secondary antibodies were as previously described [15] . We developed antibodies to distinguish four forms of PLM: total PLM, dephosphorylated PLM, PLM phosphorylated at S68 (the PKA site), and PLM phosphorylated at S63 (which, along with S68, is phosphorylated by PKC). Total PLM was detected using an antibody raised in chickens that we have described previously [15] , which we have called N1. We call the antibody to the dephosphorylated form C2 [22] .
The peptide antigen that mimicked the C-terminus of PLM was DEEEGTFRSSIRRLS(68)TRRR. To make phosphorylation-specific antibodies, phosphoserines were substituted at S63 and S68. Antibodies were generated in rabbits and affinity purified using peptides linked to agarose (Bethyl Labs). Antibodies to the phosphorylated peptides were first cleared of antibodies to the dephosphorylated peptide. We call the antibodies to the phosphorylated forms CP68 and CP63 respectively.
FITC-labelled antimouse and antirabbit IgG was supplied by Vector Laboratories Inc (Burlingame, CA). Texas Redlabelled anti-chicken IgY was supplied by Abcam (Cambridge, UK).
Immunoprecipitation of PLM
Immunoprecipitation studies were carried out exactly as described previously [15] but using the detergent ndodecyl octaethylene glycol monoether (C 12 E 8 ) at a concentration of 10 mmol/l (5.4 mg/ml, a concentration reported to preserve interactions between NKA subunits [23] ) to solubilize proteins and in all washes.
Immunofluorescence
Cells were plated onto laminin-coated coverslips for 30 min at room temperature, washed once with phosphatebuffered saline (PBS), fixed for 20 min at room temperature with 0.5% paraformaldehyde in PBS, permeabilized with 0.1% Triton X-100 in PBS, blocked with 2% defatted powdered milk in PBS, and immunolabelled. Anti-PLM IgY and anti-NKA a1 or a2 IgG were diluted 1:200 and detected with FITC-linked anti-IgG and Texas Red-linked anti-IgY.
Fluorescent images were collected with a Hamamatsu Orca ER camera on a Zeiss Axiovert 100 microscope using Improvision (Warwick, UK) OpenLab 2.0.5 software directing a piezo z-axis drive in 200-nm steps, with filter wheel control of excitation and Pinkel filter set (Omega Optical) to handle emitted wavelengths. Images were volume deconvolved and passed to Vococity (Improvision) software for three-dimensional analysis.
Statistical analysis
Quantitative data are shown as meansFstandard errors of the means (S.E.M.). Differences in mean measurements between experimental groups were tested by ANOVA followed by a t test, and differences were considered significant at the pb0.05 level.
Results
Measurement of NKA current (I P )
Whole-cell currents were measured at 0 mV using the perforated-patch technique to minimize cell dialysis. Currents due to the a1 and a2 forms of NKA (I a1 and I a2 ) were distinguished according to their sensitivity to dihydroouabain (DHO). Hence, we were able to quantify the currents of the two isoforms individually. Inhibition of I p by DHO occurred rapidly (b1 min), and recovery from inhibition was also very rapid, with an bovershootQ of I p followed by a return to the preinhibition level within 3 min.
The acute effect of the agonist forskolin on I p was assessed using the protocol described in Fig. 1A . I a1 and I a2 were measured twice with 7 min between measurements. Forskolin was applied for 4 min before measurement of I p for the second time. A current record is shown in Fig. 1B . In the absence of agonist, successive measurements gave identical values of I a1 and I a2 (Fig. 1C) .
Forskolin treatment elevates cAMP and stimulates I a1 but not I a2
Forskolin (1 Amol/l) increased cAMP from 15.0F1.6 to 27.0F3.3 pmol/mg protein, a significant increase ( pb0.05, paired t test) of 79.7F12.7%. These values are in line with cellular cAMP concentrations measured in cell lines using this method [24] .
The effect of forskolin treatment on the a1 and a2 components of I p is shown in Fig. 2A . Forskolin elicited an outward current, which is likely to reflect residual cAMPdependent chloride current that is incompletely blocked by glibenclamide and DIDS. This current is K-independent and did not interfere with the measurement of components of I p (not shown). A significant increase in I a1 followed the addition of 1 Amol/l forskolin ( pb0.05, paired t test). No change in I a2 was seen during the protocol ( pN0.05). Total I p also increased significantly ( pb0.05, paired t tests) during treatment with forskolin (not shown). The specific increase in I a1 with forskolin treatment was 36F15%. The increase in the total NKA pump current was 31F7%.
3.3. Effect of forskolin is blocked by H89, but H89 has no effect alone H89 (50 Amol/l) blocked the stimulatory effect of forskolin on I a1 (Fig. 2B) . H89 also inhibited forskolinactivated ouabain-insensitive outward currents (not shown). In addition, H89 blocked the changes in the total I p induced by treatment with forskolin, ( pN0.05, paired t tests, not shown). Fig. 2B shows that the initial I a1 measured with H89 present was 284F34 fA/pF, while Fig. 2A shows an initial I a1 of 383F51 fA/pF in the absence of H89. A significant difference caused by H89 treatment might indicate a significant acute basal regulation of NKA by PKA. However, these results were obtained in different cells from different animals, and statistical analysis indicates that I a1 was not significantly lower in the H89 exposed group ( pN0.05, unpaired t test). However, to systematically investigate whether in unstimulated myocytes, I a1 is under acute basal regulation by endogenous PKA, the effects of H89 on unstimulated I p were studied. Fig. 3 shows the effect of applying H89 (50 Amol/l) as the bagonistQ during the second measurement of I p in our standard protocol. Mean data indicate no significant change in the components of I p or total I p (not shown).
Forskolin treatment does not phosphorylate a1 but phosphorylates PLM at serine 68
We investigated the phosphorylation status of NKA subunits following treatment of guinea-pig myocytes with forskolin using isoelectric focusing gels and phosphospecific antibodies. NKA a1 subunit was separated on an IEF gel in pH range 4-7, as described previously [15] . Fig. 4A indicates that the distribution of the a1 protein between different charge states was not altered following treatment with forskolin, indicating no change in its gross phosphorylation status. We routinely observe multiple charge states for the a1 subunit by IEF [15] , however the relative distribution between these states was identical in the two treatment groups.
The phosphorylation status of serine 938 (in the PKA consensus phosphorylation site on the NKA a1 subunit) was investigated using a phosphospecific antibody to this site [25] . Fig. 4B indicates that treatment of cells with forskolin was without effect on the phosphorylation status of this residue, indicating that NKA a1 subunit is not likely to be the target for PKA in the isoform-specific stimulation of NKA that we have observed. Like other researchers [13] , we are unable to detect phosphorylation of this residue by PKA in the absence of low concentrations of detergent to unfold the a1 subunit (Fig. 4B) .
We [15] , and others [19, 26] , have recently proposed that phospholemman (PLM) forms part of the NKA enzyme complex in the heart. We therefore investigated the phosphorylation status of PLM using antibodies specific for the PKA (serine 68) and PKC (serines 63 and 68) consensus phosphorylation sites [27] on PLM. Fig. 4C indicates that, while forskolin treatment was without effect on serine 63, there was an approximately fivefold increase in the phosphorylation status of serine 68 following treatment with forskolin. There was a significant increase in I a1 in guinea-pig ventricular myocytes with forskolin treatment (*: pb0.05, paired t test) but no effect on I a2 (n=6 cells from five animals). The effect of H89 (50 Amol/l) on the response to forskolin is shown in panel (B). H89 blocked the stimulatory effect of forskolin on I a1 (n=5 cells from two animals). All recordings were made in the chloride-balanced test solution (see Materials and methods). 
Antibody characterization
We characterized antibodies to dephosphorylated (C2) [22] , serine 63 phosphorylated (CP63), and serine 68 phosphorylated (CP68) PLM by immunoblotting samples from rat ventricular myocytes treated with forskolin (100 Amol/l) and PMA (100 nmol/l) to activate PKA and PKC, respectively. PKA is reported to phosphorylate serine 68, and PKC both serines 63 and 68, of PLM [27] . We characterized the phosphospecific antibodies in rat cardiomycoytes because rat PLM has been cloned whereas guinea-pig PLM has not. However, given the high amino acid identity between cloned mammalian PLMs (the intracellular regions of rat, mouse, human, and canine PLM are 100% identical except for a single conserved substitution in murine Fig. 5 . Antibody characterization. Antibodies C2, CP63, and CP68 were characterized using PMA and forskolin-treated rat ventricular myocytes. Cells were treated with forskolin [label (F), 1 Amol/l] or PMA [label (P), 100 nmol/l] for the times indicated (in minutes) at 37 8C, immediately mixed with SDS-PAGE loading buffer, proteins separated by SDS-PAGE, and blotted using the antibody indicated. Representative blots are shown. Signals were quantitated using the NIH Image software package and normalized to the signal at time zero. Mean data (n=3 animals) are shown in bar graphs. The N1 (total PLM) antibody indicated there was equal loading of PLM in all lanes (not shown). PLM), we believe it is reasonable to extend the use of these phosphospecific antibodies to guinea-pig samples once we have established their specificity. Immunoblots are shown in Fig. 5 .
Binding of the C2 antibody is reduced when PLM is phosphorylated (Fig. 5, upper panel) . This is particularly pronounced in cells treated with PMA, which might suggest that the C2 epitope includes serine 63 but possibly not serine 68; the binding patterns of C2 and CP63 are reciprocal.
The CP63 antibody shows a substantial, sustained increase in binding following treatment with PMA (Fig.  5, middle panel) . CP68 reports phosphorylation of serine 68 in cells treated with either forskolin or PMA (Fig. 5,  bottom panel) . Serine 68 phosphorylation is better maintained in cells treated with PMA than in cells treated with forskolin. CP68 cross-reacts with another protein in cells treated with forskolin, which we believe to be serine 16 phosphorylated phospholamban. The amino acid sequences surrounding the PKA phosphorylation sites in PLM and phospholamban are very similar.
In addition to data generated with forskolin and PMAtreated rat ventricular myocytes, antibodies N1, C2, CP63, and CP68 detected no bands in immunoblots of samples from PLM-deficient mice (not shown). Using purified, unphosphorylated recombinant PLM [28] , we find that CP68 is specific for PLM phosphorylated at S68 (manuscript under preparation), but CP63 cross-reacts with unphosphorylated PLM to a small extent.
3.6. NKA a1, b1, and PKA but not a2 coprecipitate with PLM
We have recently reported an association between NKA a1 subunit and PLM in sarcolemmal preparations from rat hearts [15] . In the current study, we investigated the association between PLM and other NKA subunits by immunoprecipitation with PLM antibodies under conditions known to preserve the association between these NKA subunits [23] . When PLM was immunoprecipitated, NKA a1 but not a2 subunits were coprecipitated, as was the catalytic subunit of PKA (Fig. 6) . Treatment of cells with forskolin substantially increased the amount of PKA that copurified with PLM.
Immunofluorescent colocalization of PLM and NKA subunits
We investigated the cellular localization of NKA subunits by immunofluorescence microscopy. NKA a1 and a2 are shown in green in Fig. 7 , PLM in red, and overlap in yellow. NKA a1 and PLM are predominantly located in the peripheral sarcolemma, while NKA a2 is mainly distributed in the t-tubules. There is substantial overlap between PLM and a1 in guinea-pig ventricular myocytes; approximately 90% of PLM staining on the peripheral sarcolemma is found associated with a1 staining. Substantially less overlap is observed between PLM and a2. The subcellular distribution of NKA subunits was not altered following treatment with forskolin (not shown).
Discussion
This study indicates that, in guinea-pig ventricular myocytes, a forskolin-activated increase in cAMP is associated with a PKA-mediated a1 isoform-specific increase in NKA activity. Isoelectric focusing gels and a phosphospecific antibody for serine 938 on NKA a1 subunit suggest that PKA regulation of NKA in guineapig ventricular myocytes is not mediated through direct a1 subunit phosphorylation. Instead, we propose that phosphorylation of the small accessory protein phospholemman (PLM) by PKA at serine 68 is responsible for the observed isoform-specific activation of NKA.
We have specifically investigated the acute effect of forskolin on cardiac NKA. Under physiological conditions, the stimulation of NKA we observe may shorten the action potential duration and balance the increased sarcolemmal Na and K fluxes during adrenergic stimulation of the heart. However, the effect of prolonged activation of PKA on components of I p remains to be established.
Our striking isoform-specific observation is in agreement with other reports of a similar PKA-mediated a1 isoformspecific effect of isoprenaline in whole-cell voltage-clamped guinea-pig myocytes [9] . In addition, this study provides a second model in which PLM is found to regulate NKA activity. Previously, we established that the ouabain-sensitive ATPase activity of NKA (V max ) was activated in concert with phosphorylation of PLM by PKA in the rat heart during ischemia [15] . We now report that the ion transporting function of NKA, measured as a membrane current under aerobic conditions, is also activated concomitant with a PKA-mediated phosphorylation of PLM. The concentration of the H89 used in this study (50 Amol/l) is somewhat higher than that used by other investigators. H89 at 10 Amol/l will not discriminate between PKA and other kinases such as MSK1, S6K1, and ROCK-II [29] . While it is possible that these kinases may be involved, they have not previously been implicated in PLM phosphorylation. The combination of the effect of H89, the immunoprecipitation of PKA with PLM, the fivefold increase in phosphorylation of the PKA consensus sequence in PLM, and the known robust activation of PKA by forskolin leads us to suggest that these effects are mediated via PKA.
Intracellular Ca is critical in determining whether PKA activation causes inhibition (at Ca less than 150 nmol/l) or stimulation of NKA in guinea-pig ventricular myocytes [5] [6] [7] . Our study has avoided dialyzing cell contents by using the perforated patch technique, so Ca is not buffered. It is noteworthy that, in cardiac myocytes, PKC (among other kinases) is regulated in part by Ca. PLM is a substrate for PKC, and it has been reported that phosphorylation of PLM by PKA at serine 68 limits the ability of PKC to phosphorylate it at serine 63, indicating that PLM may be able to integrate signaling from different kinases [30] . This may explain the dependence on Ca of PKA stimulation of NKA that other authors have reported: the effect of PKA may be determined by the degree to which PLM is PKC-phosphorylated. In this study, we saw no change in the phosphorylation status of PLM at serine 63, indicating that changes in PKC activity are not relevant to the NKA stimulation we observe.
We do not observe an interaction between PLM and NKA a2 subunit. This is in contrast to other reports, which have observed functional [26] and physical [23] interactions between these proteins. We cannot rule out the possibility that NKA a2 does copurify with PLM in our immunoprecipitation experiments but in an amount that is below the level of detection by immunoblotting. However, our immunofluorescence data may shed some light on the contradiction between our data and other reports. NKA a2 subunit is targeted predominantly to the t-tubules in guinea-pig ventricular myocytes, while approximately 75% of PLM is found in the peripheral sarcolemma. Targeting of these proteins to predominantly different cellular compartments renders an interaction between them impossible. Hence, our data do not rule out that NKA a2 and PLM may associate when expressed in the same membrane compartment (for example in Xenopus oocytes [26] or regions of the CNS [23] ), or that PLM phosphorylation may effect the activity of NKA a2 when they are able to interact. In guinea-pig ventricular myocytes, PLM only interacts with NKA a1 because this is the only isoform of NKA in the same subcellular location.
The ability to regulate the activity of NKA a1 independent of a2 has important implications for cardiac function. It has been proposed that the a1 and a2 forms of NKA have distinct functional roles in cardiac physiology. Specifically, a2 NKA has been proposed to regulate Ca signaling through a functional association with the sodium-calcium exchanger [31] , although this hypothesis has been challenged [32] . Our study sheds no light on this controversy directly. However, if NKA a1 and a2 are indeed playing different roles in the physiology of the heart, it is natural to assume that the regulatory mechanisms controlling the two isoforms may be distinct. The specific functional and physical colocalization of PLM with NKA a1 but not a2 provides the means to achieve differential regulation of these NKA isoforms. The physiological significance of our observations is therefore clear: PLM is a functional component of the NKA enzyme complex, and phosphorylation of PLM modulates the ATPase and pumping function of NKA. We propose that PLM is the functional link between PKA and NKA in the heart. Given that PLM is also a substrate for PKC, it is tempting to speculate that PLM may also provide a functional link between PKC and NKA. Experiments are underway in PLM-deficient mice to test these hypotheses. The clinical significance of this observation is also clear: inhibition of PKA (through blockade of h-adrenergic receptors) and PKC (through inhibition of angiotensinconverting enzyme) improves the prognosis of patients in heart failure. A common path may be the reduced phosphorylation of PLM. Hypophosphorylation of PLM in heart failure may contribute to the elevation of intracellular Na and contractile dysfunction by modifying NKA activity. This is currently under investigation.
In summary, we propose that isoform-specific activation of NKA by PKA in guinea-pig ventricular myocytes is through phosphorylation of PLM rather than the catalytic subunits of NKA. PLM is an integral regulator of NKA in the heart.
